Figure 1
Participant countries in Central and South America.
Table 1
Information to be collected.
| Information | Variables |
|---|---|
| Demographics | Age, gender, and other variables that will allow this population to be characterized |
| Comorbidities | Mainly cardiovascular pathologies including hypertension, coronary artery disease, heart failure and dyslipidemia, among others. Other high-risk comorbidities like cancer, immunosuppressive conditions, obesity, diabetes mellitus, COPD and renal failure will be included. |
| Previous cardiovascular treatment | ARB/ACEi/ARNI, and other drugs like beta blockers, diuretics, antiplatelet and anticoagulant agents |
| Symptoms at admission | Includes the most frequently reported (fever, cough, chest pain, and fatigue) and other less frequent variables (dysphagia, loss of taste or smell, myalgias, diarrhea…) |
| Clinical findings at admission | Basic hemodynamic and metric evaluation |
| Cardiovascular complications during hospitalization | Myocarditis, arrhythmias, heart failure, coronary artery events, venous or arterial thrombosis |
| Laboratory test at admission | Complete blood count, kidney and liver function tests, cardiovascular biomarkers and inflammatory biomarkers |
| Electrocardiography | Rhythm, QRS complex, bundle, branch block, corrected QT interval |
| Chest X-Ray | Pulmonary infiltrates, cardiomegaly, lung congestion, pleural effusion |
| Echocardiography | RV systolic function, pericardial effusion, cardiac tamponade, valvular function, vena cava dilatation, measurement of LV size and LV global systolic function |
| Cardiovascular procedures performed during hospitalization | Central catheters, use of inotropes, vasopressors or vasodilators, mechanical ventilation, ventricular assist devices (IABP, ECMO) |
| COVID-19 treatment during hospitalization | Steroids, antivirals, anti-inflammatory, anticoagulant or any other used treatment |
| Laboratory tests at discharge | Complete blood count, kidney and liver function tests, cardiovascular biomarkers and inflammatory biomarkers |
| Outcomes during hospitalization and at discharge | Length of stay, condition at discharge (alive or dead) |
| Outcomes 30 days after discharge | Rehospitalization, condition at follow up (alive or dead) |
[i] COPD: Chronic Obstructive Pulmonary Disease; ARB: Angiotensin-Receptor Blockers; ACEi: Angiotensin-Converting Enzyme Inhibitors; ARNI: Angiotensin Receptor Neprilysin Inhibitor; RV: Right Ventricle; LV: Left Ventricle; IABP: Intra-Aortic Balloon Pump; ECMO: Extracorporeal Membrane Oxygenation.